Mironid's Latest Funding Round
Mironid, a biopharmaceutical company based in Glasgow, Scotland, has successfully raised $46 million in a Series B funding round. This round was led by the Scottish National Investment Bank, with participation from several notable investors including Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde.
Focus on Kidney Disease
Founded in 2015, Mironid focuses on developing innovative treatments for rare kidney diseases, inflammatory diseases, and cancer. The company is currently advancing its lead drug candidate aimed at treating Autosomal Dominant Polycystic Kidney Disease (ADPKD), a hereditary disorder affecting over 12 million people globally.
Strategic Use of Funds
The newly acquired funds will primarily be utilized to further the clinical development of Mironid's key drug candidate for ADPKD. As Neil Wilkie, CEO of Mironid, stated, "This financing will allow us to progress the clinical development of our lead candidate, bringing us closer to transforming the treatment landscape for patients with rare kidney diseases."
Leadership and Vision
CEO Neil Wilkie has emphasized the importance of this funding in validating Mironid’s approach to tackling kidney diseases. "Securing funding from such a high-calibre syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD," Wilkie noted.
Investor Confidence
The participation of high-profile investors underscores the confidence in Mironid's potential to innovate within the biopharmaceutical sector. The backing from these investors is expected to accelerate the company's efforts in bringing new treatment options to patients worldwide.